Parikh A A, Lowy A M
Division of Surgical Oncology, University of Cincinnati, 234 Goodman Street, Cincinnati, OH 45219, USA.
Curr Gastroenterol Rep. 1999 Apr;1(2):166-74. doi: 10.1007/s11894-996-0017-5.
Pancreatic cancer remains a deadly disease, with few patients surviving 5 years following diagnosis. Surgical resection remains the only treatment associated with the potential for cure; however, most patients have locally advanced or metastatic disease at presentation and thus are not surgical candidates. Advances in imaging technologies, biochemistry, and molecular genetics have raised hopes of improving the outcome for patients with pancreatic cancer through earlier and more accurate diagnosis. As our knowledge of the genetics of pancreatic cancer has increased, the possibility of screening to identify patients at risk to develop the disease also holds promise. This review focuses on the utility of current modalities to screen for pancreatic cancer as well as the most accurate and expedient methods to stage the disease.
胰腺癌仍然是一种致命疾病，诊断后很少有患者能存活5年。手术切除仍然是唯一有可能治愈的治疗方法；然而，大多数患者在就诊时已处于局部晚期或转移性疾病状态，因此不适合手术。成像技术、生物化学和分子遗传学的进展带来了通过更早、更准确的诊断来改善胰腺癌患者预后的希望。随着我们对胰腺癌遗传学知识的增加，通过筛查来识别有患该病风险的患者也具有前景。本综述重点关注当前胰腺癌筛查方法的实用性以及对该疾病进行分期的最准确、最便捷的方法。
